Show results for
Refine by
Applications
- Intraoperative Radiation Therapy (IORT) System - Electron Therapy for Skin Cancer
- Intraoperative Radiation Therapy (IORT) System for Flash Radiotherapy
- Intraoperative Radiation Therapy (IORT) System for Pancreatic Cancer Treatment
- Intraoperative Radiation Therapy (IORT) System for Breast Cancer Treatment
- Intraoperative Radiation Therapy (IORT) System for Single-Fraction APBI
- Intraoperative Radiation Therapy (IORT) System for Surgical Oncologists
- Intraoperative Radiation Therapy (IORT) System for Radiation Oncologists
- Intraoperative Radiation Therapy (IORT) System for Hospital Administrators
- Nuclear Medicine for Therapy
- Nuclear Medicine for Theragnostics
Cancer Center Celebrates 2 000 Patients Equipment & Supplies
175 equipment items found
Manufactured by:Caelus Health based inAmsterdam, NETHERLANDS
CH-0701: the fourth drug intervention is based on FMT in Cancer cachexia; the primary objective is to extend the application of FMT to late and earlier stage cancer ...
Manufactured by:Emosis Diagnostics SAS based inIllkirch-Graffenstaden, FRANCE
Primary aim is in assessing procoagulant states associated with cancer and cancer therapies, to inform physician’s decision making on initiating, pursuing or stopping anticoagulant prophylaxis in cancer patient. ...
Manufactured by:Abologix based inGeneva, SWITZERLAND
Junction Adhesion Molecule C (JAM-C) has been studied at the laboratories of Prof. Beat Imhof and Prof. Thomas Matthes at the Université de Genève for over 10+ years (36 peer reviewed publications). There is in addition 60+ publications from other laboratories. JAM-C is expressed by certain lymphocytes and prominently localises to tight junctions of endotelial cells. In many ...
Manufactured by:Abologix based inGeneva, SWITZERLAND
Olfactomedin-like protein 3 (Olfml3) creates an angiogenic environment in tumours and is associated with vascular growth factors BMP-4 and PDGF. Olfml3 is overexpressed in some cancers. Blocking Olfml3 with highly specific monoclonal antibodies is therefore a logical scientific approach in order to develop new generation inhibitors of angiogenesis. Abologix has produced several recombinant ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
The ApyraMed technology exploits a recombinant live biotherapeutic that promotes adaptive intestinal homeostasis. In cancer patients, it enhances immune system competence, whereas in dysbiosis safeguards the intestinal ...
Manufactured by:TxinnoBioscience Inc. based inYongin-si, SOUTH KOREA
Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. The first one is defined as tumor-intrinsic factors which are either genes or signaling pathways of tumor cells to directly control tumor cell proliferation or survival. Corresponding assets are ULK1 inhibitor, target S inhibitor and target Y inhibitor related to RAS signaling ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic gastrectomy in early gastric cancer ...
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, ...
Manufactured by:T-Cure BioScience, Inc. based inSherman Oaks, CALIFORNIA (USA)
Our exclusive iSORT (Isolation of Optimal Reverse Immunology Generated TCR) platform is able to isolate TCRs against unique selected tumor-associated intracellular and extracellular antigens and neoantigens in the context of an HLA molecule, allowing us to focus on specific cancers and patient populations based on their genetic makeups. Using this technology, we are able to isolate TCR ...
Manufactured by:MiraDx based inLos Angeles, CALIFORNIA (USA)
Radiation therapy is a form of cancer treatment that is used in over 2/3 of cancer patients diagnosed every year. Although generally, radiation is a safe treatment, 5-10% of patients will experience serious side effects from treatment. In addition, some patients respond not only locally to radiation, but also have an immune response that can help them to fight their cancer. Miradx is at the ...
by:RaySearch Laboratories based inStockholm, SWEDEN
Save time and reduce the risk of error by automating treatment planning. Advanced plan-generating protocols, scripting, automated breast planning, fallback planning, machine learning and plan explorer are some of the tools available in RayStation — the first treatment planning system to incorporate machine learning applications. ...
Manufactured by:IMB Dx, Inc. based inSeoul, SOUTH KOREA
AlphaLiquid®100 is a test that enables the detection of biomarkers which can predict the efficacy/resistance of targeted therapy for one blood test across 118 cancer-related genes. During cancer patients’ treatment journey, a simple blood draw can be used to support monitoring the treatment response and change the strategy when resistance biomarkers emerged. ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX22, humanised IgG1 monoclonal antibody injection targeting human epidermal growth factor receptor-2 (HER2). First patient has been dosed in Phase 2 clinical trial to compare HLX22 in combination with trastuzumab and chemotherapy as first-line therapy for HER2-positive locally advanced or metastatic gastric cancer patients in Chinese ...
by:Calviri based inPhoenix, ARIZONA (USA)
Calviri’s immunotherapy diagnostic is a huge leap forward in predicting therapy outcomes compared to current available ...
Manufactured by:BioVariance GmbH based inKonnersreuther Str. 6g, GERMANY
Using genetics to identify the best possible medication for your individual patient! OncoVariant supports physicians in interpreting the genetic alterations of their cancer patients. BioVariance has developed a web-based platform to identify the most suitable medication based on the patient’s own genetic variants. Any manual search for the most effective medication is inherently time ...
by:IBA based inLouvain-La-Neuve, BELGIUM
Proteus® has been inspired by everyday clinical practice. Through day-to-day interactions with the community, IBA is perfectly positioned to understand, and invest in, the user’s needs. These investments are directly translated into benefits for the patients. The Proteus® design enhances the patient experience by fostering a soothing environment while making the medical ...
Manufactured by:ViennaLab Diagnostics GmbH based inVienna, AUSTRIA
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI ...
Manufactured by:Trailhead Biosystems Inc. based inBeachwood, OHIO (USA)
We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s T-cells in the lab so they will attack cancer cells. If clinical development of the CART T-cell produces the wrong T-cell subtype, patient ...
by:Acuamark Diagnostics based inNew York, NEW YORK (USA)
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per year (worldwide). Annually, the worldwide economic impact of cancer is estimated by the WHO at $1.2 trillion. ...
by:B dot Medical Inc. based inEdogawa-ku, JAPAN
We are trying to overturn the image that society has of radiotherapy and proton therapy with our innovative technology. We are developing proton therapy with the hope of making it accessible to all cancer ...